Disparities in Early Access to Innovative Therapies: A Global Overview
Decision brief
Answer first · skim in under a minute
This article examines the disparities in early access to innovative therapies across major global markets, highlighting implications for stakeholders.
Disparities in Early Access to Innovative Therapies: A Global Overview show that pre-approval pathways and post-approval reimbursement still diverge across the United States, European Union, China, and Japan. For BD and investors, launch sequencing must separate regulatory clocks from payer clocks—and from uneven clinical-trial geography.
Contents11 sections
Key Takeaways
- FDA expanded access can bridge treatment gaps before approval, but sponsors must agree to supply product and FDA criteria must be met.
- EMA PRIME prioritizes medicines addressing unmet need; it does not by itself guarantee equal Member State reimbursement.
- EU Regulation (EU) 2021/2282 on health technology assessment strengthens joint clinical assessment while national pricing remains local.
- Comparative policy work (including a 2025 Frontiers in Medicine review) links early-access inequity to unmet-need definitions, review timelines, and fragmented HTA.
Why do early access pathways diverge by region?
A 2025 policy review in Frontiers in Medicine (doi:10.3389/fmed.2025.1642882) compares early and expanded access across the US, EU, China, and Japan. It argues that unequal pre-approval opportunity stems from differing unmet medical need definitions, heterogeneous review timelines, and uneven Early/Expanded Access rules—not from a single global queue.
The same review notes that tools such as FDA Breakthrough Therapy designation, EMA PRIME, Japan’s Sakigake designation, and Chinese reforms can accelerate selected products, while cross-border trial siting and HTA fragmentation still leave patients behind.
What does FDA expanded access actually require?
According to the FDA’s expanded access overview, the pathway may be appropriate when the patient has a serious or immediately life-threatening disease or condition, no comparable satisfactory alternative therapy exists, trial enrollment is not possible, potential benefit justifies potential risks, and providing the investigational product will not interfere with trials that could support marketing approval.
FDA is explicit that investigational products have not been found safe and effective for the specific use, and that unexpected serious side effects remain possible. Expanded access is therefore a controlled exception, not a substitute for development-grade evidence.
EMA PRIME and Europe’s dual clock
EMA’s PRIME: priority medicines scheme targets medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients with no existing options. Enhanced scientific and regulatory support can tighten development plans for qualifying programs.
Even after a central marketing authorization, patients still face national pricing and reimbursement steps. That second clock—not the CHMP opinion alone—often determines whether “early access” is real for a given Member State.
EU HTA Regulation 2021/2282: joint assessment, local payers
Regulation (EU) 2021/2282 on health technology assessment establishes an EU framework for joint clinical assessment and related cooperation. It is designed to reduce duplicated clinical evidence review across Member States.
- Instrument: Regulation (EU) 2021/2282 (HTA Regulation).
- Focus: joint clinical assessment and cooperation on HTA methods.
- Limit: pricing and reimbursement decisions remain national competences.
For global launch models, treat joint clinical assessment as a process efficiency layer, not a single EU price or guaranteed day-180 availability everywhere.
Japan and China: designation tools versus launch reality
Japan’s PMDA publishes English-language materials on review services and designation pathways that sponsors use to accelerate priority products, including historically recognized Sakigake-type designation concepts for innovative therapies. China’s recent reforms have shortened some innovative-drug review cycles relative to older baselines, but first-in-country trial capacity and local data expectations still shape when patients can enroll or receive expanded access.
The Frontiers comparative analysis frames these tools as accelerators “in selected contexts,” not as proof that APAC patients systematically receive the earliest global access.
Implications for BD, investors, and trial geography
Commercial teams should model three layers separately: (1) regulatory designation and review clocks, (2) pre-approval expanded/early access eligibility and sponsor willingness to supply, and (3) post-approval HTA/reimbursement. Collapsing those layers into one “global launch date” systematically overstates peak-year revenue in slower-access markets.
Trial geography matters as well. If pivotal sites concentrate in the US and Western Europe, patients in underrepresented regions lose both protocol access and the informal knowledge networks that help clinicians navigate expanded-access paperwork.
What remains unproven about “equitable early access”
Primary sources do not show a single harmonized early-access standard across the US, EU, China, and Japan in 2026. They also do not prove that PRIME, Breakthrough, or HTA joint assessment alone closes post-approval waiting times. Any claim of uniform day-count parity across all four markets should be deleted unless backed by a cited dataset for that cohort and year.
Related NovaPharma coverage
- NMPA Drug Approvals Surge in 2025: Record First Global Approvals
- Rusan Pharma Secures PMDA GMP Approval
- Areas with Risk of Dengue: CDC map, criteria, and global reach
Frequently Asked Questions
What is FDA expanded access for investigational therapies?
FDA expanded access, sometimes called compassionate use, is a pathway for patients with serious or immediately life-threatening conditions to obtain an investigational product outside trials when no satisfactory alternative exists and trial enrollment is not possible.
How does EMA PRIME affect early access in Europe?
EMA’s PRIME (priority medicines) scheme supports development of medicines that may offer a major therapeutic advantage for patients with unmet need, aiming to optimize development plans and accelerate evaluation where criteria are met.
Why do EU patients still face access gaps after approval?
Central authorization does not equal national reimbursement. EU Regulation 2021/2282 on health technology assessment creates joint clinical assessment tools, but Member State pricing and coverage decisions still drive unequal post-approval access.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
